Previous 10 | Next 10 |
13 patients treated to date have received single-agent PV-10 or combination of PV-10 and standard of care checkpoint blockade Independent safety profiles of PV-10 and checkpoint inhibition were maintained 32% ORR and 82% DCR of injected visceral hepatic target lesions (2D EASL) KNOXVI...
Noteworthy events during the week of December 8 - 14 for healthcare investors. More news on: Roche Holding AG, Athenex, Inc., Anixa Biosciences, Inc., Healthcare stocks news, , Read more ...
KNOXVILLE, TN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent for the treatment of primary or metastatic tumors of the liver ( NCT0...
First 10 checkpoint-refractory melanoma patients treated Established safety profiles of PV-10 and KEYTRUDA were maintained 20% ORR and 40% DCR (RECIST 1.1) Changes in immune system activation biomarkers of checkpoint-refractory patients were similar to those of single-agent PV-10- and P...
Full accrual of 21 checkpoint-naïve melanoma patients No safety concerns identified; no significant overlap of toxicities 95% 12-month OS rate; 100% 12-month DSS rate; Median PFS of 11.7 months 10% CR and 67% ORR (RECIST 1.1) overall; 82% ORR for Stage M1b-c KNOXVILLE, TN, Nov....
KNOXVILLE, TN, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting, cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent and in combination with standard of care checkpoint inhibition for th...
KNOXVILLE, TN, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10 ® in combination with checkpoint inhibition for the treatment of advanced cutaneous melanoma ( NCT02557...
Dr. Schmitz, General Partner of The March Fund and former Chief Science Officer of Mars, Incorporated is Provectus’ inaugural Scientific Advisory Board member KNOXVILLE, TN, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Dr. Harold Sch...
Two-stage, 34-patient, Phase 2 study combines PV-10 and Keytruda ® (pembrolizumab) for treatment of metastatic neuroendocrine tumors Combination powered for 19% ORR vs 3.7% ORR for Keytruda (KEYNOTE-158) Interim assessment conducted 24 weeks after initial treatment of 9 th patien...
Dr. Akers to assist Provectus develop and manage new Company scientific advisory board KNOXVILLE, TN, July 29, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Dr. Frank Akers to the Company’s Strategic Advisory Board (“SAB”), effecti...
News, Short Squeeze, Breakout and More Instantly...
Provectus Biopharmaceuticals Inc Company Name:
PVCT Stock Symbol:
OTCMKTS Market:
Provectus Biopharmaceuticals Inc Website:
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the “2024 Annual Meeting”), including meeting activities and ...
Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharma...
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose be...